Senti Biosciences (NASDAQ:SNTI) Trading Up 2.5% – Here’s What Happened

Shares of Senti Biosciences, Inc. (NASDAQ:SNTI) traded up 2.5% during mid-day trading on Thursday . The company traded as high as $2.34 and last traded at $2.27. 113,805 shares changed hands during trading, a decline of 83% from the average session volume of 653,933 shares. The stock had previously closed at $2.21.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Chardan Capital reiterated a “buy” rating and set a $12.00 target price on shares of Senti Biosciences in a report on Thursday, June 12th. Laidlaw assumed coverage on Senti Biosciences in a report on Friday, June 6th. They set a “buy” rating and a $5.00 target price for the company.

Senti Biosciences Stock Performance

The company has a market cap of $59.07 million, a P/E ratio of -0.21 and a beta of 2.09. The company has a fifty day moving average price of $2.98 and a two-hundred day moving average price of $3.54.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.85). The firm had revenue of $1.30 million during the quarter, compared to the consensus estimate of $1.30 million. Research analysts anticipate that Senti Biosciences, Inc. will post -14.54 EPS for the current year.

Hedge Funds Weigh In On Senti Biosciences

Hedge funds have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in Senti Biosciences during the fourth quarter worth about $47,000. Renaissance Technologies LLC bought a new position in Senti Biosciences during the fourth quarter worth about $181,000. Heights Capital Management Inc. bought a new position in Senti Biosciences during the first quarter worth about $2,520,000. Finally, Nantahala Capital Management LLC bought a new position in Senti Biosciences during the first quarter worth about $2,984,000. Institutional investors own 25.73% of the company’s stock.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.